Rima Acosta

1.1k total citations
17 papers, 512 citations indexed

About

Rima Acosta is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Rima Acosta has authored 17 papers receiving a total of 512 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 14 papers in Virology and 4 papers in Emergency Medicine. Recurrent topics in Rima Acosta's work include HIV/AIDS drug development and treatment (15 papers), HIV Research and Treatment (14 papers) and HIV/AIDS Research and Interventions (11 papers). Rima Acosta is often cited by papers focused on HIV/AIDS drug development and treatment (15 papers), HIV Research and Treatment (14 papers) and HIV/AIDS Research and Interventions (11 papers). Rima Acosta collaborates with scholars based in United States, Germany and France. Rima Acosta's co-authors include Hal Martin, Sean E Collins, Diana M. Brainard, Xuelian Wei, Paul E. Sax, Yazdan Yazdanpanah, Debbie Hagins, Kirsten White, José Ramón Arribas and Franco Maggiolo and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and Journal of Hepatology.

In The Last Decade

Rima Acosta

17 papers receiving 504 citations

Peers

Rima Acosta

VIROL

EPIDE

Amanda Clarke United Kingdom

Martin Gartland United Kingdom

Naomi Givens United Kingdom

David Piontkowsky United States

Romina Quercia United Kingdom

Juan Tiraboschi Spain

Yvon van Delft Netherlands

Kristen Andreatta United States

Corinne Rancinan France

Gianmaria Baldin Italy

Amanda Clarke United Kingdom

Rima Acosta

320 ×0.7

215 ×0.6

VIROL

134 ×0.6

57 ×0.9

EPIDE

22 ×0.6

Citations per year, relative to Rima Acosta Rima Acosta (= 1×) peers Amanda Clarke

Countries citing papers authored by Rima Acosta

Since Specialization

Citations

This map shows the geographic impact of Rima Acosta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rima Acosta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rima Acosta more than expected).

Fields of papers citing papers by Rima Acosta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rima Acosta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rima Acosta. The network helps show where Rima Acosta may publish in the future.

Co-authorship network of co-authors of Rima Acosta

This figure shows the co-authorship network connecting the top 25 collaborators of Rima Acosta. A scholar is included among the top collaborators of Rima Acosta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rima Acosta. Rima Acosta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Jucov, Alina, Tarik Asselah, Adrian Streinu‐Cercel, et al.. (2025). THU-243 SOLSTICE week 24 subgroup analysis: impact of baseline viral parameters and cirrhosis status on virological and biochemical responses in participants with chronic hepatitis delta virus infection treated with tobevibart and elebsiran. Journal of Hepatology. 82. S829–S830. 1 indexed citations

D’Antoni, Michelle L., et al.. (2023). Brief Report: Comparative Analysis of Pre-existing HIV Drug Resistance Mutations in Proviral DNA Using Next-Generation Sequencing and Routine HIV RNA Genotyping. JAIDS Journal of Acquired Immune Deficiency Syndromes. 93(3). 213–218. 2 indexed citations

Sax, Paul E., José Ramón Arribas, Chloe Orkin, et al.. (2023). Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. EClinicalMedicine. 59. 101991–101991. 46 indexed citations

Sax, Paul E., Kristen Andreatta, Jean‐Michel Molina, et al.. (2022). High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I. AIDS. 36(11). 1511–1520. 14 indexed citations

Acosta, Rima, Michelle L. D’Antoni, Andrew Mulato, et al.. (2022). Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro. Antimicrobial Agents and Chemotherapy. 66(5). e0203821–e0203821. 4 indexed citations

D’Antoni, Michelle L., Kristen Andreatta, Rima Acosta, et al.. (2021). Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes. 89(4). 433–440. 7 indexed citations

Acosta, Rima, Silvia Chang, Ross Martin, et al.. (2021). Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants. Journal of Antimicrobial Chemotherapy. 76(8). 2153–2157. 11 indexed citations

Acosta, Rima, Madeleine Willkom, Kristen Andreatta, et al.. (2020). Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance. JAIDS Journal of Acquired Immune Deficiency Syndromes. 85(3). 363–371. 20 indexed citations

Mulato, Andrew, Rima Acosta, Silvia Chang, et al.. (2020). Simulating HIV Breakthrough and Resistance Development During Variable Adherence to Antiretroviral Treatment. JAIDS Journal of Acquired Immune Deficiency Syndromes. 86(3). 369–377. 10 indexed citations

10.

Sax, Paul E., Jürgen K. Rockstroh, Anne F. Luetkemeyer, et al.. (2020). Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. Clinical Infectious Diseases. 73(2). e485–e493. 80 indexed citations

11.

Mulato, Andrew, Rima Acosta, Stephen R. Yant, Tomáš Cihlář, & Kirsten White. (2020). 1448. Forgiveness of BIC/FTC/TAF: In Vitro Simulations of Intermittent Poor Adherence Find Limited HIV-1 Breakthrough and High Barrier to Resistance. Open Forum Infectious Diseases. 7(Supplement_1). S726–S727. 2 indexed citations

12.

D’Antoni, Michelle L., Kristen Andreatta, Rima Acosta, et al.. (2020). 633. Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Efficacy in Participants with Pre-Existing Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials. Open Forum Infectious Diseases. 7(Supplement_1). S376–S377. 1 indexed citations

13.

Wohl, David A., Yazdan Yazdanpanah, Axel Baumgarten, et al.. (2019). Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The Lancet HIV. 6(6). e355–e363. 116 indexed citations

14.

Stellbrink, Hans‐Jürgen, José Ramón Arribas, Jeffrey L. Stephens, et al.. (2019). Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The Lancet HIV. 6(6). e364–e372. 99 indexed citations

15.

Kityo, Cissy, Debbie Hagins, Ellen Koenig, et al.. (2019). Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial. JAIDS Journal of Acquired Immune Deficiency Syndromes. 82(3). 321–328. 44 indexed citations

16.

Acosta, Rima, Madeleine Willkom, Ross Martin, et al.. (2019). Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks. Antimicrobial Agents and Chemotherapy. 63(5). 41 indexed citations

17.

Acosta, Rima, et al.. (1989). Sulfite sensitivity: relationship between sulfite plasma levels and bronchospasm: case report.. PubMed. 62(5). 402–5. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact